Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-023872
Filing Date
2025-05-08
Accepted
2025-05-08 16:38:01
Documents
55
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rgls-20250331.htm   iXBRL 10-Q 1234040
2 EX-31.1 ex-311x20250331.htm EX-31.1 9689
3 EX-31.2 ex-312x20250331.htm EX-31.2 9680
4 EX-32.1 ex-321x20250331.htm EX-32.1 9542
  Complete submission text file 0001628280-25-023872.txt   5525090

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rgls-20250331.xsd EX-101.SCH 33421
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rgls-20250331_cal.xml EX-101.CAL 49873
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rgls-20250331_def.xml EX-101.DEF 218058
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rgls-20250331_lab.xml EX-101.LAB 542480
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rgls-20250331_pre.xml EX-101.PRE 364681
58 EXTRACTED XBRL INSTANCE DOCUMENT rgls-20250331_htm.xml XML 562554
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

EIN.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35670 | Film No.: 25926936
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)